Cytotoxic FCER1G+ innate-like T cells: new potential for tumour immunotherapy
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2059-3635
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Cytotoxic FCER1G+ innate-like T cells: new potential for tumour immunotherapy ; volume:7 ; number:1 ; day:29 ; month:6 ; year:2022 ; pages:1-2 ; date:12.2022
Signal transduction and targeted therapy ; 7, Heft 1 (29.6.2022), 1-2, 12.2022
- Urheber
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41392-022-01061-4
- URN
-
urn:nbn:de:101:1-2022082022072525967321
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:29 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Morrish, Emma
- Ruland, Jürgen Maximilian
- SpringerLink (Online service)
Ähnliche Objekte (12)
Exploiting innate immunity for cancer immunotherapy
Imaging of tumour response to immunotherapy
HNSCC: tumour antigens and their targeting by immunotherapy
Innate Immune Activation with Multifunctional Nanoparticles for Cancer Immunotherapy
Innate Immune Activation with Multifunctional Nanoparticles for Cancer Immunotherapy
Activated innate lymphoid cell populations accumulate in human tumour tissues
Quantitative study of cytotoxic T-lymphocyte immunotherapy for nasopharyngeal carcinoma
Neoantigen-specific cytotoxic Tr1 CD4 T cells suppress cancer immunotherapy
Cytotoxic Effects of Smp24 and Smp43 Scorpion Venom Antimicrobial Peptides on Tumour and Non-tumour Cell Lines
Emerging Innate Immune Cells in Cancer Immunotherapy: Promises and Challenges
Innate immunity based cancer immunotherapy: B16-F10 murine melanoma model
Toll like receptors (TLRs) and innate immunity
Exploiting innate immunity for cancer immunotherapy
Imaging of tumour response to immunotherapy
HNSCC: tumour antigens and their targeting by immunotherapy
Innate Immune Activation with Multifunctional Nanoparticles for Cancer Immunotherapy
Innate Immune Activation with Multifunctional Nanoparticles for Cancer Immunotherapy
Activated innate lymphoid cell populations accumulate in human tumour tissues
Quantitative study of cytotoxic T-lymphocyte immunotherapy for nasopharyngeal carcinoma
Neoantigen-specific cytotoxic Tr1 CD4 T cells suppress cancer immunotherapy
Cytotoxic Effects of Smp24 and Smp43 Scorpion Venom Antimicrobial Peptides on Tumour and Non-tumour Cell Lines
Emerging Innate Immune Cells in Cancer Immunotherapy: Promises and Challenges
Innate immunity based cancer immunotherapy: B16-F10 murine melanoma model
Toll like receptors (TLRs) and innate immunity
Exploiting innate immunity for cancer immunotherapy
Imaging of tumour response to immunotherapy
HNSCC: tumour antigens and their targeting by immunotherapy
Innate Immune Activation with Multifunctional Nanoparticles for Cancer Immunotherapy
Innate Immune Activation with Multifunctional Nanoparticles for Cancer Immunotherapy
Activated innate lymphoid cell populations accumulate in human tumour tissues
Quantitative study of cytotoxic T-lymphocyte immunotherapy for nasopharyngeal carcinoma
Neoantigen-specific cytotoxic Tr1 CD4 T cells suppress cancer immunotherapy
Cytotoxic Effects of Smp24 and Smp43 Scorpion Venom Antimicrobial Peptides on Tumour and Non-tumour Cell Lines
Emerging Innate Immune Cells in Cancer Immunotherapy: Promises and Challenges
Innate immunity based cancer immunotherapy: B16-F10 murine melanoma model